MorphoSys and Merck Serono team up to develop immune checkpoint inhibitors for cancer
Executive Summary
Therapeutic antibody firm MorphoSys AG will use its Ylanthia fragment antigen-binding (Fab) library to identify antibodies against immune checkpoints for Merck KGAA’s Merck Serono SA.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
-
Drug Discovery Technologies
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice